Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the 2026 American Society of Clinical Oncology Annual Meeting - Morningstar
·
0 reactions
·
0 comments
·
10 views
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Original article
Google News
Anonymous · no account needed